Form 4: Nuvalent Director Michael L. Meyers Receives Significant Equity Grant

Nuvalent, Inc. Director Michael L. Meyers was granted 2,647 restricted stock units and options to purchase 4,147 shares of Class A Common Stock, aligning his interests with shareholders.

Summary

• Michael L. Meyers, a Director of Nuvalent, Inc. (NUVL), acquired 2,647 shares of Class A Common Stock through restricted stock units (RSUs) on June 18, 2025.
• Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock, granted at a price of $0.00.
• Additionally, Mr. Meyers was granted stock options to purchase 4,147 shares of Class A Common Stock with an exercise price of $75.53 per share, also on June 18, 2025.
• Both the RSUs and stock options vest in full on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service.
• Following these transactions, Mr. Meyers directly beneficially owns 5,146 shares of Class A Common Stock and 4,147 stock options.

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally a positive signal, indicating alignment of interests and confidence in the company's future. It's a routine compensation event but still carries positive sentiment.

Positives

• The grant of restricted stock units and stock options aligns the director's financial interests with those of the company's shareholders, incentivizing long-term performance.
• The acquisition of additional equity by a director can be viewed as a positive signal of confidence in the company's future prospects.

Future Outlook

The vesting schedule for the RSUs and stock options, tied to continued service until June 18, 2026, or the next annual meeting, indicates an expectation of continued commitment from Director Michael L. Meyers to Nuvalent, Inc.

Industry Context

Equity grants, including restricted stock units and stock options, are a standard component of executive and director compensation packages in the biotechnology and pharmaceutical industries. They are designed to attract and retain talent, and to align the interests of leadership with long-term shareholder value creation, particularly in companies like Nuvalent, Inc. which are often in growth phases and rely on long-term strategic development.

Comparison to Industry Standards

• The structure of this equity grant, involving both RSUs and stock options with a multi-year vesting schedule, is consistent with common compensation practices for directors in the U.S. biotech sector.
• While specific comparable companies or projects are not detailed in this filing, such grants are typical for directors of publicly traded companies, aiming to incentivize performance and retention.
• The exercise price of $75.53 for the options suggests it was granted at or near the market price on the grant date, which is standard for incentive stock options.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of director's interests with shareholder value creation through equity ownership and performance incentives.
• Employees: No direct impact mentioned, but a stable and incentivized board can indirectly benefit employees through better strategic direction.
• Management: Strengthens the board's commitment and oversight, potentially leading to more effective strategic decisions.

Next Steps

• Vesting of the 2,647 restricted stock units on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders.
• Vesting of the options to purchase 4,147 shares of Class A Common Stock on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders.
• Potential exercise of stock options by Michael L. Meyers before their expiration on June 18, 2035.

Key Dates

Keywords

Nuvalent, NUVL, SEC Form 4, Insider Transaction, Director Compensation, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, Corporate Governance